Global Peptide Hormone Market & Pipeline Analysis

ペプチドホルモンの世界市場及びパイプライン分析

◆タイトル:Global Peptide Hormone Market & Pipeline Analysis
◆商品コード:KUICK504223
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年4月
◆ページ数:180
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Multi User(全社内共有可)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、ペプチドホルモンの世界市場について調査・分析し、以下の構成でお届けいたします。

・ペプチドホルモンの概要
・ペプチドホルモン治療の仕組み
・ペプチドホルモンの世界市場概要
・ペプチドホルモンの世界市場動態
・ペプチドホルモンの世界市場展望
・ペプチドホルモンの開発パイプライン(治験)動向
・ペプチドホルモンの上市品分析
・停止・中止されたペプチドホルモン
・主要企業分析

Human body consists of myriad of chemicals required for signaling, providing nutrients, proper growth and development. Hormones are one such chemical present in the body that plays a very important role in maintaining homeostasis. They are secreted from endocrine glands which are also known as duct less gland because hormones are directly secreted into the blood stream. Moreover, diversity could be observed in their molecular structure, chemical nature, functionality, site of secretion and action. Among hormones, peptide hormones form an important category consisting of short amino acid chains of varying sizes. They are secreted in miniscule quantities but their effect is profound on target tissue which may be distant to the site of secretion. Despite this fact, they are indispensible in nature and investigators are trying to increase understanding about their action mechanism to come forth with suitable therapeutics.

Diseases due to deficiency of peptide hormone have been observed by investigators and cure for some of them has been marketed across the globe. Investigators have found more than 50 types of hormones in body belonging to different classes having characteristic biochemical and biophysical properties. In this way, they offer huge commercialization potential but all of them don’t have significant therapeutic benefits as compared to peptide hormones. They are customizable in nature due which they could be modulated according to the receptor molecules. As a result, their specificity increases several folds providing higher safety profile along with minimized side effects. Moreover, increased potency is among other benefits due to which lesser dosage is required for achieving higher therapeutic benefits. These favorable feature makes them a suitable candidate having significant therapeutic and commercialization potential in several disease categories.

Pharmaceutical companies have recognized the commercialization and therapeutic potential of peptide hormones for treating various diseases. As a result, they are investing more funds in research and development segment to develop novel therapeutics to fulfill high unmet medical necessities. Several peptide hormone drug development programs have been instigated by pharmaceutical companies which would help in generating significant revenues. Their administrations in several hormonal imbalances have shown proven safety and efficacy profiles leading to higher acceptance among patients. In past few years, new mechanisms have been deciphered by investigators that will offer more options to patients suffering from various peptide hormone disorders. It is expected that investigators would introduce innovative therapeutics in market due to increased funding in research and development segment.

Several years of knowledge has been gathered by investigators due to which market introduction of new peptide hormones is expected to take place in coming years. Progress has been made in improvement of peptide design and candidate molecule screening are undergoing through different phases of clinical trials. These innovative peptide hormones are expected to enter in global market in coming years for various disease categories. Due to significant therapeutic efficacy they are expected to compete effectively and erode profit of other therapeutics. Moreover, newer instruments are expected to be introduced for providing better control over quantity and quality of peptide hormones. Besides this their manufacturing capabilities are expected to increase several folds and introduction of superior technology will further allow the pharmaceutical manufacturers to achieve higher production at competitive pricing. With all these positive development, the future of peptide hormones seems to be optimistic.

“Peptide Hormones Market & Pipeline Insight 2015” Report Highlight:
• Global Peptide Hormone Market Overview
• Peptide Hormones Clinical Pipeline by Company, Indication & Phase
• Marketed Peptide Hormones by Company & Indication
• Peptide Hormones Clinical Pipeline: 47 Drugs
• Majority Peptide Hormone in Phase-II Trials: 15 Drugs
• Marketed Peptide Hormones: 24 Drugs
• Global Peptide Hormone Market Future Prospects

【レポートの目次】

1. Introduction to Peptide Hormones

2. Mechanism of Peptide Hormone Therapy

3. Global Peptide Hormone Market Overview
3.1 Current Market Scenario
3.2 Peptide Hormones Pipeline Overview

4. Global Peptide Hormone Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges

5. Global Peptide Hormone Market Future Prospects

6. Peptide Hormones Clinical Pipeline by Company, Indication & Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Phase-I
6.5 Phase-I/II
6.6 Phase-II
6.7 Phase-III
6.8 Preregistration

7. Marketed Peptide Hormones by Company & Indication

8. Discontinued & Suspended Pipeline by Company, Indication & Phase
8.1 Discontinued
8.2 Market Withdrawal
8.3 No Development Reported
8.4 Suspended

9. Competitive Landscape
9.1 BioPartners
9.2 Boehringer Ingelheim
9.3 Eli Lily
9.4 Innovate Biopharmaceuticals
9.5 Merck
9.6 NovoNordisk
9.7 Par Pharmaceuticals
9.8 Pfizer
9.9 Roche
9.10 Sanofi
9.11 Tarix Pharmaceuticals

Figure 1-1: Properties of Peptide Hormone
Figure 1-2: Therapeutic Features of Peptide Hormones
Figure 1-3: Required Improvements for Peptide Hormones
Figure 2-1: Mechanism of Peptide Hormones
Figure 2-2: Mechanism of Insulin
Figure 2-3:Mechanism of Genotropin
Figure 2-4:Mechanism of Pitressin
Figure 2-5:Mechanism of Glucagon
Figure 3-1: Peptide Hormones Pipeline by Phase (%), 2015
Figure 3-2: Peptide Hormones Pipeline by Phase (Number), 2015
Figure 3-3: No Development Reported Peptide Hormones Pipeline by Phase (%), 2015
Figure 3-4: No Development Reported Peptide Hormones Pipeline by Phase (Number), 2015
Figure 3-5: Discontinued Peptide Hormones Pipeline by Phase (%), 2015


【掲載企業】

BioPartners , Boehringer Ingelheim , Eli Lily , Innovate Biopharmaceuticals , Merck , NovoNordisk , Par Pharmaceuticals , Pfizer , Roche , Sanofi , Tarix Pharmaceuticals

【レポートのキーワード】

ペプチドホルモン、医薬品、治療、パイプライン

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[ペプチドホルモンの世界市場及びパイプライン分析]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆